Kymera Therapeutics (KYMR) Return on Sales (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Return on Sales data on file, last reported at 0.02% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.02%, up 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.07% (down 2.0% YoY), and the FY2025 annual result was 0.09%, down 3.0% from the prior year.
• Return on Sales rose to 0.02% in Q1 2026 per KYMR's latest filing, from 0.34% in the prior quarter.
• Over five years, Return on Sales peaked at 0.0% in Q4 2023 and troughed at 0.34% in Q4 2025.
• A 5-year average of 0.09% and a median of 0.05% in 2022 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2023 and 2025: Return on Sales rose 2 bps in 2023, then fell 23 bps in 2025.
• A 5-year view of Return on Sales shows it stood at 0.02% in 2022, then soared by 83 bps to 0.0% in 2023, then tumbled by 2603 bps to 0.11% in 2024, then slumped by 212 bps to 0.34% in 2025, then jumped by 93 bps to 0.02% in 2026.
• Business Quant data shows KYMR's Return on Sales at 0.02% in Q1 2026, 0.34% in Q4 2025, and 0.34% in Q3 2025.